SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: phoenix_rising who wrote (1892)4/29/2016 5:55:34 AM
From: mokelumne river  Read Replies (1) of 2026
 
Another point on the Ferring deal, Takeda was to provide $36.6M in sales milestones for the UK. Under the revised agreement with Ferring, the latter will provide $16M in regulatory and sales milestones for the Territory. The Territory includes Latin America (and certain Caribbean countries) and now the UK. But, $16M in sales milestones is what Ferring already agreed to for Latin America. So it looks to me like the company lost all the future sales milestones for the UK. Those sales milestones continue to be elusive and now dwindling. However, if Ferring is aggressive in its Territory, I would gladly pass on the sales milestones at this point.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News